Synergistic effect and condition of pegylated interferon α with paclitaxel on glioblastoma

  • Authors:
    • Myung Jin Son
    • Hyun Seok Song
    • Mi Hyun Kim
    • Ji Tae Kim
    • Chang-Mo Kang
    • Ji Won Jeon
    • Shi-Young Park
    • Yung-Jin Kim
    • Morris D. Groves
    • Kwan Park
    • Jong-Hyun Kim
    • Do-Hyun Nam
  • View Affiliations

  • Published online on: June 1, 2006     https://doi.org/10.3892/ijo.28.6.1385
  • Pages: 1385-1392
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glioblastomas are highly vascularized tumors and anti-angiogenic strategy is one of the most promising therapeutic approaches to treat brain tumors. Interferon α (IFN-α) as a single agent or combined with standard chemo-therapy has been shown to inhibit various tumors, but the effect of combination anti-angiogenic therapy on brain tumors has not been well studied. We determined the optimal dose and schedule of pegylated IFN-α (PEG-IFN-α) against U-87MG human glioblastoma cells growing orthotopically in nude mice, since several clinical trials reported that PEG-IFN-α administered at higher or lower doses was less effective. The group treated two times per week with injections of 10 KU of PEG-IFN-α for 4 weeks showed significant decreases in cell proliferation and angiogenesis. Moreover, the optimal dose and schedule of PEG-IFN-α determined in this study and combined with paclitaxel treatment potently inhibited tumor growth in vivo. The mechanisms of the significant therapeutic effects were most likely caused by directly inhibiting cell proliferation and angiogenesis, and rendering apoptosis increased. Specifically PEG-IFN-α/paclitaxel combination induced apoptosis of tumor-associated endothelial cells more than that of tumor cells. These results suggest that optimal biological dosage and scheduling of PEG-IFN-α and paclitaxel combination is a potent strategy for glioblastoma patients as a new synergistic anti-endothelial treatment.

Related Articles

Journal Cover

June 2006
Volume 28 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Son MJ, Song HS, Kim MH, Kim JT, Kang C, Jeon JW, Park S, Kim Y, Groves MD, Park K, Park K, et al: Synergistic effect and condition of pegylated interferon α with paclitaxel on glioblastoma. Int J Oncol 28: 1385-1392, 2006.
APA
Son, M.J., Song, H.S., Kim, M.H., Kim, J.T., Kang, C., Jeon, J.W. ... Nam, D. (2006). Synergistic effect and condition of pegylated interferon α with paclitaxel on glioblastoma. International Journal of Oncology, 28, 1385-1392. https://doi.org/10.3892/ijo.28.6.1385
MLA
Son, M. J., Song, H. S., Kim, M. H., Kim, J. T., Kang, C., Jeon, J. W., Park, S., Kim, Y., Groves, M. D., Park, K., Kim, J., Nam, D."Synergistic effect and condition of pegylated interferon α with paclitaxel on glioblastoma". International Journal of Oncology 28.6 (2006): 1385-1392.
Chicago
Son, M. J., Song, H. S., Kim, M. H., Kim, J. T., Kang, C., Jeon, J. W., Park, S., Kim, Y., Groves, M. D., Park, K., Kim, J., Nam, D."Synergistic effect and condition of pegylated interferon α with paclitaxel on glioblastoma". International Journal of Oncology 28, no. 6 (2006): 1385-1392. https://doi.org/10.3892/ijo.28.6.1385